用于子宫的二线子宫激素:一个随机对照试验
Naida M Cole1, Jimin J Kim, Mario I Lumbreras-Marquez
1Department of Anesthesia and Critical Care, University of Chicago Medicine, Chicago, Illinois; the Department of Anesthesiology, Perioperative and Pain Medicine and the Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts; the Epidemiology and Public Health Division, Universidad Panamericana School of Medicine, Mexico City, Mexico; the Department of Anesthesiology, Pain Management and Perioperative Medicine, Henry Ford Hospital, Detroit, Michigan; the Department of Anesthesiology, Perioperative Medicine and Pain Management, University of Miami Miller School of Medicine, Miami, Florida; and the Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, California.
甲基尔戈诺维因酸和卡博普罗斯特甲胺在剖腹产后治疗耐火性子宫瘤时表现出类似的疗效. 当催产素无效时,这两种子宫激素都是可接受的二线治疗方法.
科学领域:
- 产科和妇科 产科和妇科
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 子宫是产后出血的主要原因.
- 第二线子宫动力学对于管理耐火性子宫动力学至关重要.
- 甲基龙酸和卡尔博普罗斯特胺是常用的药物.
研究的目的:
- 为了比较甲基尔戈诺维因酸和卡博普罗斯特甲胺作为二线子宫激素的疗效.
- 为了评估它们在接受剖腹产并患有抗氧化素性子宫瘤的患者中的有效性.
主要方法:
- 在两个学术围产中心进行了一项双盲随机试验.
- 100名患有耐火性子宫肌的患者接受了甲基尔戈诺文或卡博普罗斯.
- 用0-10数值评分尺度评估子宫声调10分钟后给药.
主要成果:
- 在10分钟 (P =.76) 后,在甲基激素 (7.3±1.7) 和碳 (7.6±2.1) 之间没有观察到平均子宫度得分的显著差异.
- 额外的子宫激动使用率 (30.0%与34.0%) 和定量血液流失率 (756毫升与708毫升) 在两组之间相似.
- 在其他对子宫缩或出血的干预措施中没有发现任何差异.
结论:
- 甲基尔戈诺维因酸盐和卡博普罗斯特甲胺在改善耐火性子宫的子宫度方面表现出相似的有效性.
- 当最初的催产素治疗失败时,这两种药物都是可接受的治疗选择.
- 进一步的研究可能会探索影响治疗反应的患者特异性因素.
更多相关视频
05:46Introduction of Intracapsular Rotary-cut Procedures IRCP: A Modified Hysteromyomectomy Procedures Facilitating Fertility Preservation
Published on: January 17, 2019
06:22Ex Vivo Method for Assessing the Mouse Reproductive Tract Spontaneous Motility and a MATLAB-based Uterus Motion Tracking Algorithm for Data Analysis
Published on: September 1, 2019
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Intrauterine Drug Delivery Systems
